![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Drug Interactions with Direct Acting Antiviral Combination of Paritaprevir/Ritonavir + Ombitasvir
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 26-28, 2015, Washington, DC, USA
Prajakta Badri1, Sandeep Dutta1, Haoyu Wang1, Thomas Podsadecki1, Akshanth Polepally1, Eoin Coakley2, Amit Khatri1, Jiuhong Zha1, Yi-Lin Chiu1, Walid Awni1, Rajeev Menon1 1AbbVie Inc., North Chicago, Illinois, United States; 2Former AbbVie employee
Clinical Pharm of HIV & Hepatitis Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir: Drug Interactions with Antiretroviral Agents - (06/01/15)
Clinical Pharm of HIV & Hepatitis Assessment of Drug-Drug Interactions Between Daclatasvir and Darunavir/Ritonavir or Lopinavir/Ritonavir - (06/03/15)
![Pharm1.gif](../images/060915/060815-9/Pharm1.gif)
![Pharm2.gif](../images/060915/060815-9/Pharm2.gif)
![Pharm3.gif](../images/060915/060815-9/Pharm3.gif)
![Pharm4.gif](../images/060915/060815-9/Pharm4.gif)
![Pharm5.gif](../images/060915/060815-9/Pharm5.gif)
![Pharm6.gif](../images/060915/060815-9/Pharm6.gif)
![Pharm7.gif](../images/060915/060815-9/Pharm7.gif)
![Pharm8.gif](../images/060915/060815-9/Pharm8.gif)
![Pharm9.gif](../images/060915/060815-9/Pharm9.gif)
![Pharm10.gif](../images/060915/060815-9/Pharm10.gif)
![Pharm11.gif](../images/060915/060815-9/Pharm11.gif)
![Pharm12.gif](../images/060915/060815-9/Pharm12.gif)
![Pharm13.gif](../images/060915/060815-9/Pharm13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|